ClinicalTrials.gg
RecruitingNCT06773988Updated Jan 14, 2025

Follow-up of NIV At Home in Patients with Duchenne Muscular Dystrophy

An observational study in Duchenne Muscular Dystrophy (DMD), sponsored by Universitaire Ziekenhuizen KU Leuven. Recruiting at 1 site in Belgium. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-14.

Sponsored by Universitaire Ziekenhuizen KU Leuven · Observational

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
17
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 56 studies in Muscular Dystrophy, Duchenne with a site in Belgium — 14 open to participants now, 20 under way, 6 of them phase 3. Muscular Dystrophy, Duchenne · Belgium.

Started
2024
with 2 others
Observational
3 of 56
2 open now
Primary completion
2027-10
later than 5 of 19 live
Registered
48th of 56
by date

Among the 56 studies in Muscular Dystrophy, Duchenne with a site in Belgium, this one is one of 3 that started in 2024, is one of 3 observational ones, reaches primary completion later than 5 of the 19 other live ones, and was the 48th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

14 of the 56 studies in Muscular Dystrophy, Duchenne with a site in Belgium are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Muscular Dystrophy, Duchenne with a site in Belgium, or all of them as a file.
02

Study summary

The aim of this study is to verify whether full video home polysomnography (sleep study) with nocturnal transcutaneous CO2 monitoring is feasible in the follow-up of non-invasive ventilation (NIV) in patients with Duchenne muscular dystrophy. The researchers would like to investigate whether they could perform sufficient measurements in the home situation and see if correct decision for further treatment could be made. Furthermore, the researchers will make an analysis on the minimal requirements of measurements to make a correct decision for the treatment of these patients.

03

Conditions studied

  • Duchenne Muscular Dystrophy (DMD)

Keywords

  • Duchenne Muscular Dystrophy
  • Non-invasive ventilation
  • Feasibility
  • Home unattended full-video polysomnography
  • Transcutaneous capnography
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients are in follow-up at the Leuven University City for Sleep/wake disorders

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with DMD > 18 years using NIV
  • Signing the written

Exclusion criteria

Exclusion Criteria:

  • /
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
17 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes

Groups and cohorts

  • Adult patients with Duchenne using NIV in follow-up at the Leuven University Center for Sleep/wake

    Patients with Duchenne Muscular Dystrophy (DMD) on non-invasive ventilation (NIV) who need a yearly follow up by polysomnopgraphy

    Diagnostic Test: Monitoring of NIV at home

Interventions

  • Diagnostic testMonitoring of NIV at home

    Monitoring of NIV at home

06

What researchers measure

Primary outcomes

  1. The feasibility of full video home polysomnography (PSG) and follow-up at home in patients with DMD on NIV, identical to the sophisticated PSG in-hospital

    The primary endpoint is the feasibility of a home based full-video polysomnography for follow-up of DMD patients on NIV.

    Time frame: Yearly home polysomnopraphy and Transcutaneous CO2 measurement, for a period of 3 years

Secondary outcomes

  1. Analysis of the minimal equipment to assure a correct follow-up of NIV at home (full video PSG vs PtcCO2) measurement combined with ventilator software data vs ventilator software data vs PtcCO2 measurement)

    Time frame: 3 years

  2. Cost-benefit analysis of follow-up of NIV at home as a preparation to create a file for the Belgian health insurance (registration of time and material)

    During 3 years, the costs for performing a home based full-video PSG (relocation costs, material, physiotherapist wage) will be weighed against the benifits (patient comfort, relieving hospital ward occupation)

    Time frame: Cost-benifit analysis will be carried out at study completion, after 3 years.

  3. Amount of technical failures, i.e. PSG signals, PtcCO2 measurement, O2 saturation measurement and video monitoring.

    Checklist after each PSG

    Time frame: Performed immediately after each PSG or PtcCO2 measurement, during a period of 3 years.

  4. Patient Reported Outcomes: Experience between in-hospital PSG vs PSG at home

    Both patient and caregiver report on a 10 point likert scale, ranging from totally not to very, how mor comfortable the PSG at home was compared to the hospital PSG.

    Time frame: The PROM will be completed by the patient at each yearly PSG, during the 3 years of the ongoing study

  5. Sleep quality questionnaire: The Pittsburgh Sleep Quality Index (PSQI)

    The Pittsburgh Sleep Quality Index (PSQI) is a widely used self-report questionnaire that assesses sleep quality over a one-month time interval. Each component score of the PSQI ranges from 0 to 3, with 3 indicating the greatest dysfunction or disturbance. The seven component scores are then summed to obtain a global PSQI score, which ranges from 0 to 21. Higher scores indicate poorer sleep quality, with a score greater than 5 suggesting significant sleep difficulties

    Time frame: The PSQI will be completed by the patient at each yearly PSG and at each yearly PtcCO2 measurment, during 3 years.

  6. Home-NIV PROM: S3-NIV

    The S3-NIV questionnaire is a short, valid and repeatable self-completed tool for the routine clinical assessment of patients undergoing home NIV. The S3-NIV questionnaire provides clinicians and patients with a simple and reliable tool to assess important domains (symptoms, sleep quality and NIV-related side effects) as a complement to physiological monitoring. The S3-NIV questionnaire has 11 items. Each item is scored using a 5-point Likert scale from "always true" to "never true". The total score and the two sub scores range from 0 to 10 points. Lower scores represent a higher, negative impact of the disease and NIV on the individual.

    Time frame: The S3-NIV questionnaire will be completed by the patient at each yearly PSG and at each yearly PTCO2 measurement, during 3 years.

  7. Daytime sleepiness questionnaire: Epworth Sleepiness Scale (ESS)

    The ESS is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different activities.

    Time frame: The ESS questionnaire will be completed by the patient at each yearly PSG and each yearly PtcCO2 measurement, during 3 years.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Bruyneel M, Ninane V. Unattended home-based polysomnography for sleep disordered breathing: current concepts and perspectives. Sleep Med Rev. 2014 Aug;18(4):341-7. doi: 10.1016/j.smrv.2013.12.002. Epub 2013 Dec 12. PubMed 24388970 ↗
  • Toussaint M, Chatwin M, Soudon P. Mechanical ventilation in Duchenne patients with chronic respiratory insufficiency: clinical implications of 20 years published experience. Chron Respir Dis. 2007;4(3):167-77. doi: 10.1177/1479972307080697. PubMed 17711917 ↗
  • Bourke SC. Respiratory involvement in neuromuscular disease. Clin Med (Lond). 2014 Feb;14(1):72-5. doi: 10.7861/clinmedicine.14-1-72. No abstract available. PubMed 24532751 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Oct 2027, 34 months after the start.

Of 52 non-industry observational studies under Muscular Dystrophy, Duchenne, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 120. This study's planned 34 months is close to that.

Counting every sponsor, half of 63 studies reached it within 40 months; a quarter within 12 and three quarters within 120.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2024
First posted
Jan 14, 2025
StartActual
Dec 6, 2024
Primary completionEst.
Oct 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Jan 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06773988
Responsible party
Sponsor
First posted
Jan 14, 2025
Start date
Dec 6, 2024
Primary completion
Oct 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jan 14, 2025

Study contacts

Dries Testelmans, MD PHD
Contact
dries.testelmans@uzleuven.be
+3216342522
Bart Vrijsen, PT PHD
Contact
bart.vrijsen@uzleuven.be
+3216342522

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion